Analytical Data
-
Gene name
ALDOS
- Application
-
Alternative Names
CPN2; CYP11B; CYP11BL; CYP11B2; P450C18; P450aldo; Steroid 18-hydroxylase; Aldosterone-synthesizing enzyme; Cytochrome P450 Family 11 Subfamily B Polypeptide 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P19099
-
Expression Region
Gly25~Asn503
-
Molecular Weight
59kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ALDOS, or aldose reductase, is an enzyme that plays a critical role in carbohydrate metabolism by catalyzing the reduction of aldoses to their corresponding alcohols, thereby influencing pathways related to glucose and polyol metabolism. Research on recombinant ALDOS has garnered significant attention due to its implications in various pathophysiological conditions, including diabetic complications, cardiovascular diseases, and neuropathies. The expression of recombinant ALDOS allows for high-yield production and detailed biochemical characterization, enhancing our understanding of its structure-function relationships. Additionally, given the enzyme's involvement in the polyol pathway, its activity is linked to oxidative stress and cellular damage, making it a potential therapeutic target for mitigating complications associated with diabetes. The investigation of ALDOS through recombinant technology offers insights into its regulatory mechanisms, interactions with other biomolecules, and potential inhibitors, paving the way for new treatment strategies. Overall, the study of recombinant ALDOS not only contributes to fundamental biochemical knowledge but also holds promise for advancing therapeutic interventions in metabolic disorders.
